Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.
Foord E, Klynning C, Schoutrop E, Förster JM, Krieg J, Mörtberg A, Müller MR, Herzog C, Schiegg D, Villemagne D, Fiedler U, Snell D, Kebble B, Mattsson J, Levitsky V, Uhlin M. Foord E, et al. Among authors: fiedler u. J Immunol Res. 2020 Aug 4;2020:7375947. doi: 10.1155/2020/7375947. eCollection 2020. J Immunol Res. 2020. PMID: 32832572 Free PMC article.
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.
Rao L, De Veirman K, Giannico D, Saltarella I, Desantis V, Frassanito MA, Solimando AG, Ribatti D, Prete M, Harstrick A, Fiedler U, De Raeve H, Racanelli V, Vanderkerken K, Vacca A. Rao L, et al. Among authors: fiedler u. Oncotarget. 2018 Jan 30;9(17):13366-13381. doi: 10.18632/oncotarget.24351. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568363 Free PMC article.
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. Baird RD, et al. Among authors: fiedler u. J Clin Oncol. 2021 Jan 10;39(2):145-154. doi: 10.1200/JCO.20.00596. Epub 2020 Dec 10. J Clin Oncol. 2021. PMID: 33301375 Free PMC article. Clinical Trial.
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Fischer S, Götze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. Fischer S, et al. Among authors: fiedler u. JCO Precis Oncol. 2022 Nov;6:e2200006. doi: 10.1200/PO.22.00006. JCO Precis Oncol. 2022. PMID: 36331248 Free PMC article. No abstract available.
Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study.
Ribaldi F, Altomare D, Jovicich J, Ferrari C, Picco A, Pizzini FB, Soricelli A, Mega A, Ferretti A, Drevelegas A, Bosch B, Müller BW, Marra C, Cavaliere C, Bartrés-Faz D, Nobili F, Alessandrini F, Barkhof F, Gros-Dagnac H, Ranjeva JP, Wiltfang J, Kuijer J, Sein J, Hoffmann KT, Roccatagliata L, Parnetti L, Tsolaki M, Constantinidis M, Aiello M, Salvatore M, Montalti M, Caulo M, Didic M, Bargallo N, Blin O, Rossini PM, Schonknecht P, Floridi P, Payoux P, Visser PJ, Bordet R, Lopes R, Tarducci R, Bombois S, Hensch T, Fiedler U, Richardson JC, Frisoni GB, Marizzoni M. Ribaldi F, et al. Among authors: fiedler u. Magn Reson Imaging. 2021 Feb;76:108-115. doi: 10.1016/j.mri.2020.11.008. Epub 2020 Nov 19. Magn Reson Imaging. 2021. PMID: 33220450
125 results